The Clorox Company
NYSE:CLXHousehold & Personal Products
-$2.54 today
- Market cap
- $13.13B
- Beta
- 0.55
- P/E (TTM)
- 15.2
- EPS (TTM)
- $6.23
- Dividend yield
- 5.22%
Volume 2.16M
Average 2.84M
CLX Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
The Clorox CompanyNYSE: CLX
Research & Development · Q1 FY2027 · quarter ended Sep 2026
Research & development growth accelerates
Q1 FY2027 research & development of $29M rose 3.6% year over year, ahead of the -0.8% change in trailing-twelve-month research & development. Sequentially, it fell 9.4% from the prior quarter. Over 3 fiscal years it compounded at -5.6% a year.
Context
- Research & development amounted to 1.7% of revenue in FY2026, unchanged from a year earlier.
- Research & development increased in 0 of the last 3 fiscal years.
- FY2026 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +3.6% holds above the trailing-twelve-month pace of -0.8%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2026
- 116M USD
- Year-over-year change
- -4.1%
- 4-year CAGR
- -3.2%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2026 | 2026-06-30 | 116M | -4.1% |
| FY2025 | 2025-06-30 | 121M | -4.0% |
| FY2024 | 2024-06-30 | 126M | -8.7% |
| FY2023 | 2023-06-30 | 138M | +4.5% |
| FY2022 | 2022-06-30 | 132M | — |
Research & Development vs competitors
How CLX compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -0.8% is the 2nd highest of 6, against a peer median of -100.0%.
- Research & development amounts to 1.6% of revenue for CLX, versus a peer median of 0.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $180M USD | — | — | 1.2% | |
| LTM Sep 2026 | $117M USD | -0.8% | -5.6% | 1.6% | |
| LTM Mar 2026 | $58.5M USD | -0.3% | +1.2% | 2.8% | |
| LTM Jun 2026 | $10.7M USD | -59.8% | — | 0.4% | |
| LTM Sep 2026 | $0 USD | — | — | 0.0% | |
| FY2025 | €0 EUR | — | — | 0.0% | |
| LTM Sep 2026 | $0 USD | -100.0% | +4.6% | 0.0% | |
| LTM Jun 2026 | $0 USD | -100.0% | — | 0.0% | |
| LTM Sep 2026 | $0 USD | — | — | 0.0% | |
| LTM Jun 2026 | $0 USD | — | — | 0.0% | |
| LTM Feb 2026 | $0 USD | -100.0% | +4.1% | 0.0% | |
| Peer median (excluding CLX) | — | -100.0% | +4.1% | 0.0% | |
Competitors are the stored peer set for CLX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Jun 2022 | FY2023 Jun 2023 | FY2024 Jun 2024 | FY2025 Jun 2025 | FY2026 Jun 2026 |
|---|---|---|---|---|---|
| Revenue | 7.11B | 7.39B | 7.09B | 7.1B | 6.72B |
| Cost of Revenue | 4.56B | 4.48B | 4.05B | 3.89B | 3.88B |
| Gross Profit | 2.55B | 2.91B | 3.05B | 3.21B | 2.84B |
| Gross Margin | 35.8% | 39.4% | 43.0% | 45.2% | 42.3% |
| Research & Development | 132M | 138M | 126M | 121M | 116M |
| Selling, General & Admin | 1.66B | 1.92B | 2.17B | 1.89B | 1.07B |
| Operating Expenses | 1.83B | 2.09B | 2.33B | 2.04B | 1.18B |
| Depreciation & Amortization | 224M | 236M | 235M | 219M | 247M |
| EBITDA | 937M | 564M | 723M | 1.39B | 1.17B |
| EBITDA Margin | 13.2% | 7.6% | 10.2% | 19.5% | 17.4% |
| Operating Income | 719M | 823M | 723M | 1.18B | 1.66B |
| Operating Margin | 10.1% | 11.1% | 10.2% | 16.6% | 24.7% |
| Interest Income | 5M | 16M | 23M | 9M | 8M |
| Interest Expense | 106M | 90M | 90M | 88M | 130M |
| Other Income / Expenses | (112M) | (585M) | (325M) | (99M) | (871M) |
| Income Before Tax | 607M | 238M | 398M | 1.08B | 791M |
| Pre-Tax Margin | 8.5% | 3.2% | 5.6% | 15.2% | 11.8% |
| Income Tax Expense | 136M | 77M | 106M | 254M | 190M |
| Net Income | 462M | 149M | 280M | 810M | 587M |
| Net Margin | 6.5% | 2.0% | 3.9% | 11.4% | 8.7% |
| EPS (Basic) | 3.75 | 1.21 | 2.25 | 6.56 | 4.82 |
| EPS (Diluted) | 3.73 | 1.20 | 2.25 | 6.52 | 4.81 |
| Weighted Avg Shares | 123.11M | 123.59M | 124.17M | 123.53M | 121.78M |
| Weighted Avg Shares (Diluted) | 123.91M | 124.18M | 124.8M | 124.29M | 122.13M |
The Clorox Company
NYSE:CLX
Intrinsic Alpha fair value
Locked
Current Price
$108.39
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.